TriSalus Life Sciences opened at $2.30, in line with its previous close of $2.30. In the last trading session, the stock traded between $2.21 and $2.49. It showed an upward intraday trend.
An investment of $100 made 4 years ago in TriSalus Life Sciences is now worth
$ 21.02
Resulting in a loss of
$ 78.98 (78.98%)
Note: Past profits do not guarantee future returns.
Rating from 3 Analysts
Today's Change
+$0.22 (+9.65%)
Day High
$2.49
Day Low
$2.21
Day Open
$2.30
Prev Close
$2.30
Volume
4,76,584
1W Return
-35.23%
1M Return
-39.16%
3M Return
-55.99%
6M Return
-44.45%
1Y Return
-41.89%
Market Cap ($ Mn)
156
PE Ratio
-
PB Ratio
45.42
PEG Ratio
-
ROE
-
ROCE
-152.83%
EPS (TTM)
$-0.14
1 Week
-35.23%
1 Month
-39.16%
3 Months
-55.99%
6 Months
-44.45%
9 Months
-47.46%
Canaccord Genuity lowers TriSalus Life Sciences price target to $4
Canaccord Genuity maintains a Buy rating on TriSalus Life Sciences. Price target lowered from $7 to $4 by analyst William Plovanic. No change in investment recommendation despite reduced valuation.
YesterdayHC Wainwright maintains Buy on TriSalus, cuts price target to $10
HC Wainwright maintains a Buy rating on TriSalus Life Sciences. Price target lowered from $12 to $10 by analyst Swayampakula Ramakanth. No change to the investment recommendation despite target cut.
YesterdayTriSalus Life Sciences Q3FY26 Results: Revenue up 11.3% to $12.9M
Revenue rose 11.3% YoY to $12.9 million driven by increased TriNav unit sales. Gross margins expanded to 86.2% from 83.5% due to lower cost per unit. Operating losses narrowed to $7.7 million from $9.0 million in the prior year. Full-year 2026 revenue guidance revised to $46 million-$48 million. FDA cleared TriNav Advance for use in small distal vessels.
2 days agoTriSalus Life Sciences schedules Q3FY26 results call for November 10
TriSalus Life Sciences will host a conference call on November 10, 2026, at 8:30 am ET. The call will discuss financial results for the quarter ended September 30, 2026. A press release detailing the results will be issued prior to the conference call. Participants can join via phone after registering online or watch the live webcast.
23 days agoTriSalus Life Sciences posts $11.4M Q2 revenue, EBITDA loss widens
Revenue rose 1.7% YoY to $11.4 million in Q2 2026. Adjusted EBITDA loss widened to $7.1 million due to sales force expansion. CMS approved G code extending TRINAV reimbursement to office-based labs. Full-year 2026 revenue guidance reiterated at $54 million to $57 million. Cash position stands at $46.3 million, funding strategic growth plan.
1mo agoTriSalus shares rise 5.8% on FDA clearance for TriNav Advance
TriSalus Life Sciences received FDA 510(k) clearance for TriNav Advance. Shares rose 5.8% to $5.22 on Wednesday following the announcement. TriNav Advance expands PEDD portfolio to small, distal vessels. Stock trades above all major moving averages but faces resistance at $6.00. Benzinga Edge Momentum score stands at 77.29, indicating bullish sentiment.
1mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $109.29 | -1.06% | $1,89,283.94M | 36.28 | |
| $449.53 | -0.11% | $1,55,826.88M | 42.73 | |
| $101.61 | +0.02% | $1,29,976.46M | 24.46 | |
| $318.79 | -1.70% | $1,21,360.48M | 34.27 | |
| $45.13 | +0.96% | $65,414.72M | 18.96 | |
| $105.81 | +1.73% | $60,840.75M | 53.70 | |
| $214.52 | +0.90% | $58,432.46M | 44.07 | |
| $82.60 | -1.26% | $37,346.60M | 16.49 | |
| $42.16 | +3.06% | $37,044.18M | 89.05 | |
| $72.46 | -2.16% | $35,027.16M | 54.55 | |
| $237.20 | +1.61% | $33,458.08M | 23.04 | |
| $80.35 | +0.53% | $29,964.75M | 36.04 |
An investment of $100 made 4 years ago in TriSalus Life Sciences is now worth
$ 21.02
Resulting in a loss of
$ 78.98 (78.98%)
Note: Past profits do not guarantee future returns.
